Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol

Niren K Shah1, Steven M Smith, Wilmer W Nichols

  • 1East Coast Institute for Research, Jacksonville, FL 32223, USA. niren@eastcoastresearch.net

Insights

Carvedilol offers superior cardiovascular benefits over atenolol by improving arterial compliance and reducing wave reflections, unlike atenolol which increased arterial stiffness. This study compared the effects of these two beta-blockers on blood pressure characteristics.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Central aortic pressure and arterial stiffness are key predictors of cardiovascular events.
  • The differential impact of various beta-blockers on these hemodynamic parameters requires further investigation.

Purpose of the Study:

  • To compare the effects of controlled-release carvedilol and atenolol on central aortic pressure and arterial stiffness in patients with essential hypertension.

Main Methods:

  • Randomized trial involving 41 patients with essential hypertension.
  • Force-titrated daily administration of carvedilol (80 mg) or atenolol (100 mg) for 4 weeks.
  • Assessment of central and brachial blood pressure, augmentation index, and pulse pressure amplification.

Main Results:

  • Both carvedilol and atenolol similarly reduced central and brachial systolic and diastolic blood pressure.
  • Atenolol significantly increased the central augmentation index, whereas carvedilol did not.
  • Carvedilol demonstrated a more favorable effect on pulse pressure amplification compared to atenolol.

Conclusions:

  • Carvedilol enhances arterial compliance and reduces wave reflection magnitude more effectively than atenolol.
  • These findings suggest carvedilol may offer superior cardiovascular protection by improving arterial properties.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...